Back in May, Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that the Government of Uruguay, through IRCCA approved Plandai Biotechnology Uruguay S.A. an interim license to design a scientific program for the R&D of prescription CBD medicines. Ferrere Abogados, the legal counsel represented Plandai throughout the licensing process.
This license will enable company to undertake in murine and vitro investigations, extending to human trials once the preliminary research has been concluded. Previously, the company obtained permission to cultivate, process and harvest live cannabis for the formulation of Phytofare™ CBD complexes in September 2014.
Dyadic International, Inc. (OTCMKTS:DYAI) Reports 2Q 2015 Financial Results
Dyadic International, Inc. (OTCMKTS:DYAI) a global biotechnology firm focused on the development, manufacture and commercialization of enzymes and other proteins released financial results for the three-months ended June 30, 2015. The first half revenue surged 30% YOY and gross profit jumped 50% YOY.
Dyadic launched biogas Enzyme Product in Europe and confirmed the receipt of second as well as third BASF research objectives. The company received and reached a settlement with one defendant pertaining to Its Professional Liability Litigation. For the record, settlement came in the favor of Dyadic. At the end of quarter, cash and cash equivalents stood at nearly $5 million against $2.5 million at end of December 31, 2014.
Entia Biosciences Inc (OTCMKTS:ERGO) Names Carl J. Johnson As Chief Executive Officer
Entia Biosciences Inc (OTCMKTS:ERGO) reported that Carl J. Johnson has been appointed as the President and Chief Executive Officer of the company. He is also elected as a member of the Board of Directors.
Mr. Johnson possesses extensive experience in managing the launch and marketing of health-related products. He has served on several leadership roles where he last was a President and CEO of Matrixx Initiatives, Inc. Mr. Johnson will significantly contribute in Entia’s growth plans and his previous experience will add commercial discipline to future plans.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: